FDA Advisory Committee Recommends Approval of Gardasil in Males
- 00:08:50
- NewsInfusion
FDA Advisory Committee Recommends Approval of Gardasil in Males
September 9, 2009 - Merck & Co., Inc. announced today that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee agreed that efficacy, immunogenicity and safety data from clinical trials in males support the use of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] in boys and men 9 through 26 years of age for the prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11. More on FDA Advisory Committee Recommends Approval of Gardasil in Males
NewsInfusion | October 20, 2009
FDA Approves Expanded Uses for GARDASIL in Preventing Cancer
New CDC Study Supports Safety Profile Of Gardasil HPV Vaccine
FDA Approves Use Of Gardasil In Boys And Young Men
FDA Approves Expanded Uses for GARDASIL in Preventing Cancer
FDA Approves Expanded Uses for GARDASIL in Preventing Cancer
FDA Approves Expanded Uses for GARDASIL in Preventing Cancer
Previous Page
Next Page
